Crystalline Solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.
1 . A crystalline solid form of Compound 1:
wherein said crystalline solid form is Form II and said Form II is characterized by an x-ray powder diffraction pattern (CuKα) comprising peaks at 6.4, 8.6, 14.9, and 20.2 (°2θ±0.2° 2θ); or at 11.6, 12.1, 12.6, 12.9, and 14.9 (°2θ±0.2°2θ); or at 6.4, 11.6, 12.1, 12.6, 12.9, 14.8, 14.9, and 20.2 (°2θ±0.2°2θ); or at 6.4, 11.6, 12.1, 12.6, 12.9, 14.8, 14.9, 18.0, 18.8, and 20.2 (°θ0+0.2 °2θ), wherein measurement is at room temperature.
2 . The crystalline solid form of Compound 1 designated as Compound 1 Form II as recited in claim 1 , wherein said Form II is characterized by an x-ray powder diffraction pattern (CuKα) comprising peaks at 6.4, 8.6, 14.9, and 20.2 (°2θ±0.2° 2θ), wherein measurement is at room temperature.
3 . The crystalline solid form of Compound 1 designated as Compound 1 Form II as recited in claim 1 , wherein said Form II is characterized by an x-ray powder diffraction pattern (CuKα) comprising peaks at 11.6, 12.1, 12.6, 12.9, and 14.9 (°2θ±0.2 °2θ), wherein measurement is at room temperature.
4 . The crystalline solid form of Compound 1 designated as Compound 1 Form II as recited in claim 1 , wherein said Form II is characterized by an x-ray powder diffraction pattern (CuKα) comprising peaks at 6.4, 11.6, 12.1, 12.6, 12.9, 14.8, 14.9, and 20.2 (°2θ±0.2° 2θ), wherein measurement is at room temperature.
5 . The crystalline solid form of Compound 1 designated as Compound 1 Form II as recited in claim 1 , wherein said Form II is characterized by an x-ray powder diffraction pattern (CuKα) comprising peaks at 6.4, 11.6, 12.1, 12.6, 12.9, 14.8, 14.9, 18.0, 18.8, and 20.2 (°2θ±0.2° 2θ), wherein measurement is at room temperature.
6 . The crystalline solid form of Compound 1 designated as Compound 1 Form II as recited in claim 1 , wherein said Form II is characterized by an x-ray powder diffraction pattern (CuKα) substantially in accordance with the pattern shown in FIG. 7 .
7 . A pharmaceutical composition comprising a therapeutically effective dose of a substantially pure crystalline solid form of Compound 1 designated as Compound 1 Form II as recited in claim 1 , and a pharmaceutically acceptable carrier.
8 . A pharmaceutical formulation comprising:
Ingredient
(% w/w)
Compound 1 Solid Form II as recited in
31.68
claim 1
Microcrystalline Cellulose
38.85
Lactose anhydrous
19.42
Hydroxypropyl Cellulose
3.00
Croscarmellose Sodium
3.00
Total Intra-granular
95.95
Silicon dioxide, Colloidal
0.30
Croscarmellose Sodium
3.00
Magnesium Stearate
0.75
Total
100.00.
9 . A pharmaceutical formulation comprising:
Ingredient
(% w/w)
Compound 1 Solid Form II as recited
25.0-33.3
in claim 1
Microcrystalline Cellulose
q.s
Hydroxypropyl Cellulose
3
Poloxamer
0-3
Croscarmellose Sodium
6.0
Colloidal Silicon Dioxide
0.5
Magnesium Stearate
0.5-1.0
Total
100.
10 . A pharmaceutical formulation comprising:
Theoretical
Quantity
(mg/unit
Ingredient
dose)
Compound 1 Solid Form II as recited
100.0
in claim 1
Microcrystalline Cellulose PH-102
155.4
Lactose Anhydrous 60M
77.7
Hydroxypropyl Cellulose, EXF
12.0
Croscarmellose Sodium
24
Colloidal Silicon Dioxide
1.2
Magnesium Stearate (Non-Bovine)
3.0
Opadry Yellow
16.0
Total
416.
11 . A pharmaceutical formulation comprising:
Ingredient
% w/w
Compound 1 Solid Form II as recited
31.7
in claim 1
Microcrystalline Cellulose
38.9
(Avicel PH-102)
Lactose Anhydrous (60M)
19.4
Hydroxypropyl Cellulose (EXF)
3.0
Croscarmellose Sodium (Ac-Di-Sol)
6.0
Colloidal Silicon Dioxide
0.3
Magnesium Stearate
0.75
Opadry Yellow Film Coating
4.00.
which includes:
HPMC 2910/Hypromellose 6 cp
Titanium dioxide
Triacetin
Iron Oxide Yellow